Axi-cel
Phase 2Cell therapy
Axi-cel is one of 57 small molecule programs targeting B-cell Lymphoma. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
64 competitors in Relapsed/refractory
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Rituxan
RochePhase 2
Venclexta
AbbViePhase 2
Fludara
SanofiPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Gemzar
Johnson & JohnsonPhase 2
Adcetris
PfizerPhase 2
Thalomid
Bristol-Myers SquibbPhase 2
Eloxatin
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
CAR1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Axi-cel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- MM.D. Anderson Cancer Center